{"id":25999,"date":"2023-12-13T18:07:33","date_gmt":"2023-12-13T12:37:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25999"},"modified":"2024-09-17T16:59:46","modified_gmt":"2024-09-17T11:29:46","slug":"phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel","title":{"rendered":"Cilta-cel Demonstrates Prolonged and Deep Responses across Advanced Treatment Lines, Signifying Potential in Early Lenalidomide-Refractory Multiple Myeloma"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>11th December 2023<\/td><\/tr>
Indications<\/td>Multiple Myeloma<\/td><\/tr>
Abstract Number<\/td>1063<\/td><\/tr>
Abstract type<\/td>Oral<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

According to the findings presented at the ASH 2023, the CARTITUDE-4 trial included a cohort of 419 patients. As of the clinical cut-off, 99 patients in the CARVYKTI arm and 66 in the standard of care (SOC) arm underwent both baseline and 12-month patient-reported outcome (PRO) assessments, capturing data before disease progression. Initial PRO compliance stood at 100%, showing a gradual decline in subsequent visits to 74% in the CARVYKTI arm and 81% in the SOC arm at the 12-month milestone. <\/p>\n\n\n\n

Throughout the analysis, patients in the CARVYKTI arm reported improved functioning and symptom reduction from baseline, while PRO scores in the standard of care (SOC) regimens, pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) arm trended toward worsening or lower degrees of improvement from baseline for most domains and symptoms.<\/p>\n\n\n\n

KOL Insights<\/strong><\/h2>\n\n\n\n

\u201cThese results from the CARTITUDE-4 study showed the potential of cilta-cel to significantly improve health-related quality of life measures for patients, including pain, fatigue, and emotional functioning. Cilta-cel has demonstrated deep and durable responses in later lines of therapy, and these results show the potential of cilta-cel for patients with lenalidomide-refractory multiple myeloma as early as after first relapse.\u201d\u2013Expert Opinion.<\/strong><\/p>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

Ciltacabtagene autoleucel has exhibited profound and lasting responses in advanced treatment lines. These findings underscore the potential of cilta-cel for patients facing lenalidomide-refractory multiple myeloma, even as early as following the initial relapse.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 11th December 2023 Indications Multiple Myeloma Abstract Number 1063 Abstract type Oral According to the findings presented at the ASH 2023, the CARTITUDE-4 trial included a cohort of 419 patients. As of the clinical cut-off, 99 patients in the CARVYKTI arm and 66 in the standard of care (SOC) arm underwent […]<\/p>\n","protected":false},"author":6,"featured_media":26049,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21525,21534,21533,137,841,927,18921,410,16669],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-25999","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-hematology","tag-multiple-myeloma","tag-multiple-myeloma-market","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nAnalysis of Phase 3 CARTITUDE-4 Study of Cilta-cel | ASH 2023<\/title>\n<meta name=\"description\" content=\"Phase 3 CARTITUDE-4 Study of Cilta-cel in Patients with Lenalidomide-Refractory Multiple Myeloma after 1\u20133 Lines of Therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Analysis of Phase 3 CARTITUDE-4 Study of Cilta-cel | ASH 2023\" \/>\n<meta property=\"og:description\" content=\"Phase 3 CARTITUDE-4 Study of Cilta-cel in Patients with Lenalidomide-Refractory Multiple Myeloma after 1\u20133 Lines of Therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-13T12:37:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T11:29:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180727\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Analysis of Phase 3 CARTITUDE-4 Study of Cilta-cel | ASH 2023","description":"Phase 3 CARTITUDE-4 Study of Cilta-cel in Patients with Lenalidomide-Refractory Multiple Myeloma after 1\u20133 Lines of Therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel","og_locale":"en_US","og_type":"article","og_title":"Analysis of Phase 3 CARTITUDE-4 Study of Cilta-cel | ASH 2023","og_description":"Phase 3 CARTITUDE-4 Study of Cilta-cel in Patients with Lenalidomide-Refractory Multiple Myeloma after 1\u20133 Lines of Therapy","og_url":"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-13T12:37:33+00:00","article_modified_time":"2024-09-17T11:29:46+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180727\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel","url":"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel","name":"Analysis of Phase 3 CARTITUDE-4 Study of Cilta-cel | ASH 2023","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180727\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel.png","datePublished":"2023-12-13T12:37:33+00:00","dateModified":"2024-09-17T11:29:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Phase 3 CARTITUDE-4 Study of Cilta-cel in Patients with Lenalidomide-Refractory Multiple Myeloma after 1\u20133 Lines of Therapy","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180727\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180727\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel.png","width":1200,"height":800,"caption":"Phase 3 CARTITUDE-4 Study"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/13180727\/phase-3-cartitude-4-study-of-ciltacabtagene-autoleucel-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Multiple Myeloma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma<\/span>","<span class=\"advgb-post-tax-term\">Multiple Myeloma Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 13, 2023","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on Dec 13, 2023 6:07 pm","modified":"Updated on Sep 17, 2024 4:59 pm"},"featured_img_caption":"Phase 3 CARTITUDE-4 Study","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25999"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25999\/revisions"}],"predecessor-version":[{"id":29574,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25999\/revisions\/29574"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26049"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25999"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25999"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}